IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

40399/321/NIHD

In re patent application of

Jeffrey RUBIN et al.

Serial No. 08/477,983

Group Art Unit: 1646

Filed: June 7, 1995

Examiner: Saoud

For:

AN EPITHELIAL CELL SPECIFIC

GROWTH FACTOR KERATINOCYTE

GROWTH FACTOR (KGF)

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

TRANSMITTAL

Transmitted herewith is an Amendment in the above-captioned application. The fee has been calculated as shown below. (Small entity fees indicated in parentheses.)

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims	34	-	27	7	18.00	126.00
(Small Entity)					(9.00)	
Independent claims	2	-	3	0	78.00	.00
(Small Entity)					(39.00)	
Multiple Dependent	0		0	0	260.00	.00
(Small Entity)					(130.00)	
Total						\$126.00

SECH CENTER 1600/2900 RECEIVED

ATTORNEY DOCKET NO.: 040399/0321

APPLN. NO.: 08/477983

No fee is believed to be due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 19-0741.

Respectfully submitted,

Patricia D. Granados Reg. No. 33,683

Dated: November 20, 1998

Foley & Lardner Washington Harbour 3000 K Street, N.W. Washington, D.C. 20007 Phone: (202) 672-5538

Fax: (202) 672-5399

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ICE Sun

40399/321/NIHD

In re patent application of

Jeffrey RUBIN et al.

Serial No. 08/477,983

Group Art Unit: 1646

Filed: June 7, 1995

Examiner: Saoud

For:

AN EPITHELIAL CELL

SPECIFIC GROWTH FACTOR KERATINOCYTE GROWTH

FACTOR (KGF)

SUPPLEMENTAL AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. § 1.129

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

This is in further response to the final rejection of August 5, 1997 and supplements the filing under § 1.129 of August 28, 1998. Applicants do not believe that any petition for extension of time or further fees are currently due. In the event this is not correct, the Commissioner is hereby authorized to debit the undersigned's charge account No. 19-0741. Please amend the application, as follows:

IN THE ORIGINAL SPECIFICATION

At page 103, line 13, please delete "BamH1/BclI fragment containing the majority" and insert –647 bp EcoRI fragment from the 5' end—

IN THE CLAIMS

Please cancel claims 13-14, 23-24, 29, 36-37, 39 and 40-43, without prejudice or disclaimer and add the following new claims: